Alan Shaw and the Food-from-Fuel Bet

The decisive moment in Alan Shaw’s second biotechnology company sounded less like a board meeting than a punchline. Calysta was working with methanotrophs, naturally occurring microbes that use methane as their carbon source. The plan was to make chemicals. Then Shaw and his colleagues noticed the more immediate product sitting in the fermenter: the microbial cells themselves were protein.

Shaw burst out laughing. He had spent years in the bioeconomy trying to turn biomass and crop waste into fuel while defending the work against an obvious criticism: food should not be diverted into fuel tanks. Now the logic had flipped. “My god, I just spent half my life trying to defend fuel from food,” he recalled, “and now here we have food from fuels.”

It was funny because it was neat, and because industrial biotechnology is almost never neat. A useful reaction has to escape the lab, survive scale-up, satisfy regulators, find partners, reach a warehouse, and arrive at a price a customer will pay. Shaw’s career has unfolded inside that less photogenic distance between a promising process and an ordinary purchase order.

“Great inventions can wither on the vine. The trick is connecting them with real need.”Alan Shaw

The market hiding inside the science

The Calysta process begins with a microbe rather than a crop or an animal. In a fermenter, methanotrophs consume a carbon source and multiply. The biomass is harvested and dried into FeedKind, a protein ingredient designed for animal-feed markets including aquaculture and pet food. The organism is non-GMO. The process uses no arable land and no plant or animal ingredients.

Fermentation is familiar. Bread, beer, and yogurt all depend on microbes doing useful work under controlled conditions. Calysta changes the feedstock and the destination. Its microbes consume methane, and the resulting cells are the product. Shaw later distinguished this “biomass fermentation” from precision fermentation, where a microorganism is programmed to produce a particular molecule. Here, the whole cultivated biomass matters.

The entrepreneurial insight was to stop earlier. Calysta did not need to push the biology onward to a chemical intermediate. In Shaw’s telling, this is the job: see where an innovation meets pain in the world. Aquaculture was expanding while its feed industry needed dependable protein sources that did not compete for farmland or rely on additional wild-caught fish. A cell in a vessel could answer a constraint outside it.

An industrial education

Shaw came to the insight with the résumé of a chemist who had spent a long time near customers. He studied chemistry at Teesside University and earned a doctorate in chemistry from Durham. At ICI and Zeneca, he moved through scientific and management posts, eventually working in fine chemicals and European sales. Later came operating and business-development roles at Chiroscience, Clariant, and BTP.

The mixture is revealing. Shaw is a Fellow of the Royal Society of Chemistry and also a Fellow of the Chartered Institute of Marketing. One credential signals command of matter. The other signals attention to demand. His public description of entrepreneurship sits at their intersection: an invention is not rescued by cleverness alone. Someone must care.

In 2002, Shaw became president and CEO of Codexis, the enzyme-engineering company he helped found. Codexis developed biocatalysts for pharmaceutical production and later pursued biofuels and bio-based chemicals. Under Shaw, it grew beyond its startup origins, established operations across the United States, Europe, and Asia, and went public on Nasdaq in 2010. That same year he received Ernst & Young’s Northern California Entrepreneur Of The Year award in life sciences. Codexis also shared a U.S. EPA green-chemistry award for a biocatalytic approach to producing chiral alcohols.

Codexis was Shaw’s first proof that difficult biology could become an industrial company. It also taught the harsher lesson that a platform must keep finding applications with economics strong enough to carry it. When he emerged at Calysta in 2012, the initial thesis again focused on fuels and chemicals, this time using methane as a cheaper and more available source of carbon.

The pivot, then the patience

In 2014, Calysta acquired BioProtein A/S and rights to a process that DuPont and Statoil had spent years developing. It was a pragmatic move. Rather than pretend every valuable piece had to be invented in-house, Calysta combined a proven gas-fermentation process with its own biotechnology platform. Shaw invested his own money after the acquisition, calling it a large personal bet.

The pilot came next, in a location with personal symmetry. In 2016, Calysta opened a facility in Teesside, Shaw’s hometown in northeast England. The plant made samples for prospective customers and gave the technical team room to improve production. Shaw stood at its opening and insisted that the fermenter represented manufacturing, not a chemistry experiment.

That distinction matters. A sample proves possibility. A plant exposes every assumption. Gas must arrive consistently. Organisms must behave at volume. Product must meet specification batch after batch. Customers need enough material for trials, then enough for contracts. The facility became a bridge between the elegant diagram and the stubborn physical world.

In 2020, Calysta and animal-nutrition company Adisseo formed Calysseo to commercialize FeedKind for Asian aquaculture. The joint venture paired Calysta’s process with Adisseo’s manufacturing and distribution reach. Its first industrial facility in Chongqing switched on in 2022 with two fermenters, each rated at 10,000 tonnes of annual nameplate capacity.

A working plant did not erase the next constraints. Feed ingredients need regulatory clearance market by market. FeedKind received U.S. FDA GRAS status for aquaculture in 2023. China’s agriculture ministry approved it for fish and shrimp feed in January 2024. An export permit followed. By August, Calysta said the first major shipment of FeedKind Pet had reached its warehouse in Poland and initial commercial deliveries to European manufacturers were complete.

In early 2025, Marsapet launched a complete dog food using FeedKind Pet. The ingredient had crossed an important, quiet threshold: from a founder’s story about a strange fermenter to something listed on a product label.

“Do you have a better idea?”

Shaw’s leadership philosophy is unusually compatible with the complexity of the work. He has written that he values teamwork and loyalty, and that he does not need to be the smartest person in the room. If he has selected the team properly, he argues, someone else should be. The practical question he wants heard is, “Do you have a better idea?”

Industrial biotechnology rewards that posture. Microbiology, process design, regulation, construction, nutrition, sales, and financing each produce their own experts and their own vetoes. The limiting problem changes as a company advances. A founder who insists on owning every answer eventually becomes the bottleneck.

Shaw’s other recurring principle is scale. He has said there is little point in a feed ingredient that cannot be mass-produced. Aquaculture feed is a large-volume market, and adoption depends on buyers believing that supply will remain available. The challenge is not merely creating a sustainable kilogram. It is making enough tonnes, reliably, for customers to redesign procurement around it.

“If I have done my job well and chosen my team carefully it should be someone else, or I’m in the wrong room!”Alan Shaw, on being the smartest person present

The second act is execution

Shaw has spoken of wanting at least a million tonnes of Calysta protein in the world. The distance from 20,000 tonnes of nameplate capacity to that aspiration is large. It contains more factories, partners, approvals, customers, and inevitable revisions. Some of Calysta’s earlier timelines proved optimistic, as early industrial forecasts often do. The physical evidence has nevertheless accumulated: pilot output, a joint venture, operating fermenters, regulatory clearances, exports, and commercial products.

This is what makes his story useful beyond alternative protein. The celebrated part of entrepreneurship is seeing what others missed. Shaw did that when a methane-to-chemicals process revealed a protein business. The durable part is accepting how many different forms the problem will take after the insight. First the organism. Then the vessel. Then the permit. Then the shipment. Then repeat demand.

A chemist can describe the transformation inside the fermenter. A marketer can describe the need outside it. Shaw’s career has been an attempt to keep those two descriptions connected long enough for a new industry to form. The laugh in 2014 was the moment the pieces aligned. Everything since has been the work of making the joke tangible.